Add to ORKGDuring a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated for sepsis in a 24-bed medical-surgical intensive care unit. Drotrecogin alfa, activated was administered 46 times to 44 patients (3% of all intensive care
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...
OBJECTIVE: To assess the cost-effectiveness of drotrecogin alfa (activated) therapy, which was recen...
Severe sepsis syndrome has important consequences to healthcare systems as the incidence is increasi...
During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated fo...
OBJECTIVE: To provide further evidence for the efficacy and safety of drotrecogin alfa (activated) t...
Administration of drotrecogin alfa (activated) has been demonstrated to reduce mortality in patients...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for ...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
A number of management issues confront the clinician treating a critically ill patient with drotreco...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...
OBJECTIVE: To assess the cost-effectiveness of drotrecogin alfa (activated) therapy, which was recen...
Severe sepsis syndrome has important consequences to healthcare systems as the incidence is increasi...
During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated fo...
OBJECTIVE: To provide further evidence for the efficacy and safety of drotrecogin alfa (activated) t...
Administration of drotrecogin alfa (activated) has been demonstrated to reduce mortality in patients...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for ...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
<p><b>Copyright information:</b></p><p>Taken from "Drotrecogin alfa (activated) in severe sepsis: a ...
A number of management issues confront the clinician treating a critically ill patient with drotreco...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
Drotrecogin alfa (activated) is a new agent that may substantially affect the treatment of patients ...
OBJECTIVE: To assess the cost-effectiveness of drotrecogin alfa (activated) therapy, which was recen...
Severe sepsis syndrome has important consequences to healthcare systems as the incidence is increasi...